DOTTIKON ES: +57% or +42.5% profit!

What are the decisive arguments for a promising stock recommendation with exceptionally high price potential? We can think of two main reasons: 1. the management should be good and credible. With its know-how, it can successfully convince business partners even in difficult phases. 2. the products are unique, difficult to copy and appreciated by customers. Both are true for DOTTIKON ES, the contract manufacturer for pharmaceutical and chemical active ingredients! For the shareholder, it was and is only a matter of time before successes occur, which are crowned with higher share prices, among other things... this is what happened with DOTTIKON ES.

The business figures presented by DOTTIKON ES at the end of May were quite something. Net sales climbed by +18.1% year-on-year to CHF 385.2 million and net profit by +30.9% to CHF 105.6 million. The market was not expecting any significant change and was therefore pleasantly surprised. The share appreciated the success and exploded within just a few days with a price increase of over +30%... and we realized our first profit! Most recently, we bought DOTTIKON ES shares on April 3, 2025 at CHF 184.20 and sold two shares on June 12 at a price target of CHF 289 , resulting in an outstanding performance of +57%! In relation to the average purchase price of CHF 202.86, this results in a gain of +42.5%! The future continues to look bright for the company: Annual growth of +7% is expected for DOTTIKON ES' small molecule-based active pharmaceutical ingredients (APIs) segment. The Group intends to accommodate this high growth with higher production capacity. The company is also offering shareholders a tour of the new facilities, which will take place on July 4. The response is likely to be positive; the company management is convincing! We see further upside potential and are therefore raising our price target to CHF 330!